Associations - MET (MET proto-oncogene, receptor tyrosine kinase)

MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	tepotinib Sensitive: A1 - Approval tepotinib Sensitive : A1	tepotinib Sensitive: A1 - Approval tepotinib Sensitive : A1
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	capmatinib Sensitive: A1 - Approval capmatinib Sensitive : A1	capmatinib Sensitive: A1 - Approval capmatinib Sensitive : A1
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	savolitinib Sensitive: A1 - Approval savolitinib Sensitive : A1	savolitinib Sensitive: A1 - Approval savolitinib Sensitive : A1
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	APL-101 Sensitive: A1 - Approval APL-101 Sensitive : A1	APL-101 Sensitive: A1 - Approval APL-101 Sensitive : A1
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	gumarontinib Sensitive: A1 - Approval gumarontinib Sensitive : A1	gumarontinib Sensitive: A1 - Approval gumarontinib Sensitive : A1
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	tepotinib Sensitive: A2 - Guideline tepotinib Sensitive : A2	tepotinib Sensitive: A2 - Guideline tepotinib Sensitive : A2
MET amplification	Renal Cell Carcinoma	MET amplification	Renal Cell Carcinoma	savolitinib Sensitive: A2 - Guideline savolitinib Sensitive : A2	savolitinib Sensitive: A2 - Guideline savolitinib Sensitive : A2
MET expression	Gastroesophageal Junction Adenocarcinoma	MET expression	Gastroesophageal Junction Adenocarcinoma	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B
MET amplification	Gastroesophageal Junction Adenocarcinoma	MET amplification	Gastroesophageal Junction Adenocarcinoma	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B
MET expression	Gastric Adenocarcinoma	MET expression	Gastric Adenocarcinoma	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B
MET amplification	Gastric Adenocarcinoma	MET amplification	Gastric Adenocarcinoma	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B
MET mutation	Renal Cell Carcinoma	MET mutation	Renal Cell Carcinoma	savolitinib Sensitive: B - Late Trials savolitinib Sensitive : B	savolitinib Sensitive: B - Late Trials savolitinib Sensitive : B
EGFR wild-type + MET overexpression	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type + MET overexpression	Lung Non-Squamous Non-Small Cell Cancer	ABBV-399 Sensitive: B - Late Trials ABBV-399 Sensitive : B	ABBV-399 Sensitive: B - Late Trials ABBV-399 Sensitive : B
MET overexpression + KDR overexpression	Ovarian Cancer	MET overexpression + KDR overexpression	Ovarian Cancer	bevacizumab Resistant: B - Late Trials bevacizumab Resistant : B	bevacizumab Resistant: B - Late Trials bevacizumab Resistant : B
MET elevation	Hepatocellular Cancer	MET elevation	Hepatocellular Cancer	cabozantinib tablet Resistant: B - Late Trials cabozantinib tablet Resistant : B	cabozantinib tablet Resistant: B - Late Trials cabozantinib tablet Resistant : B
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	MYTX-011 Sensitive: B - Late Trials MYTX-011 Sensitive : B	MYTX-011 Sensitive: B - Late Trials MYTX-011 Sensitive : B
MET exon 14 mutation	Lung Adenocarcinoma	MET exon 14 mutation	Lung Adenocarcinoma	tepotinib Sensitive: C1 - Off-label tepotinib Sensitive : C1	tepotinib Sensitive: C1 - Off-label tepotinib Sensitive : C1
MET exon 14 mutation	Lung Adenocarcinoma	MET exon 14 mutation	Lung Adenocarcinoma	capmatinib Sensitive: C1 - Off-label capmatinib Sensitive : C1	capmatinib Sensitive: C1 - Off-label capmatinib Sensitive : C1
MET exon 14 mutation	Lung Adenocarcinoma	MET exon 14 mutation	Lung Adenocarcinoma	savolitinib Sensitive: C1 - Off-label savolitinib Sensitive : C1	savolitinib Sensitive: C1 - Off-label savolitinib Sensitive : C1
MET exon 14 mutation	Gastric Cancer	MET exon 14 mutation	Gastric Cancer	tepotinib Sensitive: C1 - Off-label tepotinib Sensitive : C1	tepotinib Sensitive: C1 - Off-label tepotinib Sensitive : C1
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	bevacizumab + crizotinib Sensitive: C2 – Inclusion Criteria bevacizumab + crizotinib Sensitive : C2	bevacizumab + crizotinib Sensitive: C2 – Inclusion Criteria bevacizumab + crizotinib Sensitive : C2
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	gumarontinib Sensitive: C2 – Inclusion Criteria gumarontinib Sensitive : C2	gumarontinib Sensitive: C2 – Inclusion Criteria gumarontinib Sensitive : C2
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	gefitinib + CT053PTSA Sensitive: C2 – Inclusion Criteria gefitinib + CT053PTSA Sensitive : C2	gefitinib + CT053PTSA Sensitive: C2 – Inclusion Criteria gefitinib + CT053PTSA Sensitive : C2
MET amplification	Gastric Cancer	MET amplification	Gastric Cancer	TPX-0022 Sensitive: C2 – Inclusion Criteria TPX-0022 Sensitive : C2	TPX-0022 Sensitive: C2 – Inclusion Criteria TPX-0022 Sensitive : C2
MET mutation	Gastric Cancer	MET mutation	Gastric Cancer	TPX-0022 Sensitive: C2 – Inclusion Criteria TPX-0022 Sensitive : C2	TPX-0022 Sensitive: C2 – Inclusion Criteria TPX-0022 Sensitive : C2
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	osimertinib + savolitinib Sensitive: C2 – Inclusion Criteria osimertinib + savolitinib Sensitive : C2	osimertinib + savolitinib Sensitive: C2 – Inclusion Criteria osimertinib + savolitinib Sensitive : C2
MET amplification	Lung Cancer	MET amplification	Lung Cancer	tepotinib Sensitive: C2 – Inclusion Criteria tepotinib Sensitive : C2	tepotinib Sensitive: C2 – Inclusion Criteria tepotinib Sensitive : C2
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	APL-101 Sensitive: C2 – Inclusion Criteria APL-101 Sensitive : C2	APL-101 Sensitive: C2 – Inclusion Criteria APL-101 Sensitive : C2
MET positive	Solid Tumor	MET positive	Solid Tumor	GST-HG16 Sensitive: C2 – Inclusion Criteria GST-HG16 Sensitive : C2	GST-HG16 Sensitive: C2 – Inclusion Criteria GST-HG16 Sensitive : C2
MET mutation	Non Small Cell Lung Cancer	MET mutation	Non Small Cell Lung Cancer	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2

MET (MET proto-oncogene, receptor tyrosine kinase)

Associations(320)

Associations
(320)